About Lasa Supergenerics Limited
Data last updated:
Lasa Supergenerics Limited is a public limited company based in Khed, Maharashtra, India, a subsidiary of Omkar Speciality Chemicals Limited. It operates in the animal pharmaceuticals and healthcare segment of the pharmaceuticals sector. It was incorporated on 11 March 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24233MH2016PLC274202. Its GSTIN is 27AADCL0382Q1Z2 (Maharashtra). The company holds 2 GST registrations, of which 1 is active. It is recorded as listed by MCA, but trading in its shares on BSE (540702) has been suspended, so they do not currently trade on a stock exchange.
The company has an authorised share capital of ₹100.33 Cr and a paid-up capital of ₹5.01 Cr. It is led by directors including Omkar Pravin Herlekar (Managing Director) and Ketan Bhau Songal.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Khed, Maharashtra.
As per the financials filed for FY 2026, the company reported a revenue of ₹25.34 Cr, a decline of 82% compared to the previous year. For the same year it recorded a net loss of ₹13.05 Cr (net margin -51.5%) and EBITDA of -₹28.4 Cr (EBITDA margin -112.1%). Revenue has declined at a compounded annual rate (CAGR) of 42% over three years and 34% over five years.
The company has about 326 employees on its provident fund (EPFO) records.
As per MCA filings, the company has satisfied charges of ₹84.64 Cr on record. Court records list 44 cases involving the company, including 33 filed by the company and 11 filed against it; 10 cases are pending. The company has 29 deals on record (29 market trades); the latest was in September 2025. Its 4 peer companies in the Pharma industry (Animal Pharma), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 3 smaller; the largest is Brilliant Bio Pharma Private Limited with revenue of ₹174.32 Cr. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 507 overdue payments to 52 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lasalabs.com.
Company details
CIN history
Lasa Supergenerics has one previous CIN (Corporate Identification Number): U24233MH2016PLC274202. The current CIN is L24233MH2016PLC274202, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233MH2016PLC274202 | Current |
| U24233MH2016PLC274202 | Previous |
Contact details
Lasa Supergenerics Limited's registered office is in Khed, Maharashtra. Its website is lasalabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No. C – 4 C – 4/1 MIDC Lote Parshuram Industrial Area Tal – Khe, D, Khed, Maharashtra, India – 415722
- IndustryPharma, Animal Pharmaceuticals & Healthcare
To see the full contact details of Lasa Supergenerics Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Lasa Supergenerics is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Lasa Supergenerics Limited, buy the company report.
Financials of Lasa Supergenerics Limited
FY 2026 filings availableLasa Supergenerics Limited reported revenue of ₹25.34 Cr (down 82% YoY) for FY 2026.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 34% over five years, including a 82% fall in the latest year. EBITDA fell 202% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹25.34 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹28.4 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹13.05 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -112.1% | ||||
| Net Profit Margin | -51.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Lasa Supergenerics Limited, buy the company report.
Board of directors of Lasa Supergenerics Limited
Lasa Supergenerics has 6 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Omkar Pravin Herlekar Also directs: Lasa Lifesciences Private Limited, Dr. Omkar Herlekar Foundation | Managing Director | 11 Mar 2016 | 10 Years 7 Months | Current |
| Ketan Bhau Songal | Director | 04 Aug 2025 | 1 Years 2 Months | Current |
| Pravin Gadalya Lachake | Director | 04 Aug 2025 | 1 Years 2 Months | Current |
| Yogesh Hari Ughada | Director | 04 Aug 2025 | 1 Years 2 Months | Current |
| Rekha Hemant Wakh | Director | 04 Aug 2025 | 1 Years 2 Months | Current |
| Ganesh Suresh Potdar | Additional Director | 02 Jan 2026 | 0 Years 9 Months | Current |
Peer comparison
Lasa Supergenerics Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Animal Pharma), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Brilliant Bio Pharma Private Limited | ₹174.32 Cr (FY 2025) | 85.0% | Hyderabad, Telangana, India | |||
| Vital Therapeutics Private Limited | ₹145.15 Cr (FY 2025) | -14.0% | Secunderbad, Telangana, India | |||
| Quadragen Vethealth Private Limited | ₹133.64 Cr (FY 2025) | -18.0% | Bangalore, Karnataka, India | |||
| Harshvardhans Laboratories Private Limited | ₹123.35 Cr (FY 2025) | 12.0% | Dhar, Madhya Pradesh, India | |||
| Lasa Supergenerics Limitedthis company | ₹25.34 Cr (FY 2026) | -₹13.05 Cr | -51.5% | -82.0% | 326 | Khed, Maharashtra, India |
To see the full peer comparison of Lasa Supergenerics Limited, buy the company report.
Auditor
Lasa Supergenerics Limited is audited by THANAWALA & Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| THANAWALA & Co | FY 2023 | 110948W |
Shareholding
The shareholding of Lasa Supergenerics Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Lasa Supergenerics Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Apr 2018 | 100235964 | Others | ₹6.03 Cr | Satisfied | |
| 31 Mar 2018 | 100170282 | Others | ₹1.82 Cr | Satisfied | |
| 28 Nov 2012 | 10391228 | Axis Bank Limited | ₹76.79 Cr | Satisfied |
To see the full charge records of Lasa Supergenerics Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Lasa Supergenerics Limited has 29 deals on record (29 market trades); the latest was in September 2025.
Deals on record (5 of 29)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2023 | Market trade | ₹82.8 Lakh | Buyer: Palak Intermediates Private Limited Seller: Palak Intermediates Private Limited |
| Feb 2023 | Market trade | ₹2.25 Cr | Buyer: Palak Intermediates Private Limited Seller: Palak Intermediates Private Limited |
| Sep 2022 | Market trade | ₹1.36 Cr | Buyer: Skse Securities Limited Seller: Skse Securities Limited |
| Jan 2022 | Market trade | ₹4.43 Cr | Buyer: Olga Trading Private Limited Seller: Bnp Enterprises, Olga Trading Private Limited |
| Jun 2018 | Market trade | ₹1.43 Cr | Buyer: NBN Fintrade Private Limited Seller: Athlan Partners, NBN Fintrade Private Limited |
To see the full deal history of Lasa Supergenerics Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Lasa Supergenerics Limited has 44 court cases on record: 33 filed by Lasa Supergenerics, 11 filed against it. 10 cases are pending and 34 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 21 | 4 | 5 |
| District courts | 11 | 6 | 5 |
| NCLAT | 8 | 0 | 0 |
| NCLT | 4 | 1 | 0 |
Cases on record (5 of 44)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed by the company against Shreegen Pharma Limited | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed against the company by DPB Antibiotics Pvt Ltd and Ors | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed against the company by Shreegen Pharma Limited | Pending |
| High Court, MAHARASHTRA | Court case (CRR) | Filed by the company against Shreegen Pharma Limited and Ors | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Civil suit | Filed against the company by Dasaldhan Chemicals Pvt. Ltd. Th. Dasharath V. Ayare | Pending |
To see the full case history of Lasa Supergenerics Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Lasa Supergenerics Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 507 overdue payments to 52 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 52)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| SMD Speciality Chemicals LLP | |||
| an individual supplier | |||
| an individual supplier | |||
| Atharv Chemicals |
To see the full MSME payment records of Lasa Supergenerics Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Lasa Supergenerics Limited has a workforce of 326 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.
GST
Lasa Supergenerics has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AADCL0382Q1Z2 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Lasa Supergenerics Limited, buy the company report.
Recent activity
Lasa Supergenerics Limited has 31 board changes on record since 2016: 19 appointments and 12 cessations. The latest: Ganesh Suresh Potdar was appointed as Additional Director on 02 Jan 2026.
29 earlier events are in the company report.
News
Frequently asked questions
Lasa Supergenerics is an active public limited company based in Khed, Maharashtra, India. The company works in animal pharmaceuticals and healthcare, within the pharma industry. It was incorporated on 11 March 2016 (10+ years old) and is registered under CIN L24233MH2016PLC274202.
Lasa Supergenerics has 6 current directors:
- Omkar Pravin Herlekar - Managing Director
- Ketan Bhau Songal - Director
- Pravin Gadalya Lachake - Director
- Yogesh Hari Ughada - Director
- Rekha Hemant Wakh - Director
- Ganesh Suresh Potdar - Additional Director
The latest financial statements of Lasa Supergenerics on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Lasa Supergenerics is 27AADCL0382Q1Z2, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Lasa Supergenerics is L24233MH2016PLC274202. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Lasa Supergenerics is recorded as a listed company by MCA, but trading in its shares on BSE (540702) has been suspended, so they do not currently trade on a stock exchange.
Lasa Supergenerics has 44 court cases on record: 33 filed by the company and 11 filed against it. 10 are pending. Most are in the high courts.
Lasa Supergenerics was incorporated on 11 March 2016, making it 10+ years old. It is registered with the Registrar of Companies, Mumbai.
Lasa Supergenerics has 29 deals on record (29 market trades); the latest was in September 2025.
The peers of Lasa Supergenerics by revenue are Brilliant Bio Pharma Private Limited, Vital Therapeutics Private Limited, Quadragen Vethealth Private Limited, Harshvardhans Laboratories Private Limited, all in the Pharma industry (Animal Pharma), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Ganesh Suresh Potdar was appointed as Additional Director on 02 Jan 2026. Ajay Hareshlal Sukhwani ceased to be Director on 04 Aug 2025. Ekta Avtar Gurnasinghani ceased to be Director on 04 Aug 2025. Lasa Supergenerics has 31 board changes on record in total.
Lasa Supergenerics has 12 MSME Form 1 returns on record between 2019 and 2024, listing 507 overdue payments to 52 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
